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ABSTRACT   26 
Currently, the most effective tuberculosis control method resides in case-finding and 6 27 
months chemotherapy. There is a need to improve our understanding about drug interactions, 28 
combination activities and the ability to remove persistent bacteria in the current regimens, 29 
particularly in relation to relapse. We aimed to investigate the therapeutic effects of three 30 
main components, rifampicin (RMP), isoniazid (INH), and pyrazinamide (PZA), in current 31 
drug regimens using a modified version of the Cornell mouse model. We evaluated the post-32 
treatment levels of persistent Mycobacterium tuberculosis in the organs of mice using culture 33 
filtrate derived from M. tuberculosis strain H37Rv. When RMP was combined with INH, 34 
PZA or INH-PZA, significant additive activities were observed compared to each of the 35 
single drug treatments. However, the combination of INH and PZA showed a less significant 36 
additive effect than either of the drugs used on their own. Apparent culture negativity of 37 
mouse organs was achieved at 14 weeks of treatment with RMP-INH, RMP-PZA and RMP-38 
INH-PZA but not with INH-PZA, when conventional tests, namely culture on solid agar and 39 
in liquid broth indicated that the organs were bacteria negative. The relapse rates for RMP-40 
containing regimens were not significantly different to a 100% relapse rate at the numbers of 41 
mice examined in this study. In parallel, we examined the organs for the presence of culture 42 
filtrate-dependent persistent bacilli after 14 weeks of treatment.  Culture filtrate treatment of 43 
the organs revealed persistent M. tuberculosis.  Modelling of mycobacterial elimination rates 44 
and evaluation of culture-filtrate dependent organisms showed promise as surrogate methods 45 
for efficient factorial evaluation of drug combinations in tuberculosis in mouse models and 46 
should be further evaluated against relapse. The presence of culture filtrate-dependent 47 
persistent M. tuberculosis is the likely cause of disease relapse in this modified Cornell 48 
mouse model. 49 
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INTRODUCTION  52 
Tuberculosis (TB) remains a major killer worldwide and  is  responsible for approximately 53 
two million deaths annually (1). The main obstacle for successful disease control resides in 54 
the ability of M. tuberculosis to persist in the host despite host immune responses and 55 
chemotherapy.   Prolonged multi-drug antimicrobial therapy is necessary to achieve a cure, 56 
which leads to poor patient compliance, high relapse rates (7 - 13%) and the emergence of 57 
drug-resistance (2).  Although short course TB therapy has been in clinical use for nearly four 58 
decades, the drug interactions and the ability to remove persistent bacteria with the current 59 
regimens have not been clearly demonstrated. Previous work in the murine Cornell model has 60 
shown that after 7 weeks of intensive treatment with isoniazid (INH) and pyrazinamide (PZA) 61 
to induce a latent infection, the follow-up treatment with rifampicin (RMP) alone, RMP-INH, 62 
RMP-PZA or RMP-INH-PZA exhibited very similar anti-tuberculosis activities (3). However, 63 
another study found that when mice were treated with INH-RMP-PZA, INH-RMP or RMP-64 
PZA for 6 months, the RMP-PZA treated group demonstrated significantly lower relapse 65 
rates than the INH-RMP-PZA or INH-RMP groups (4). This study suggested that INH 66 
antagonised the actions of RMP-PZA (4) because INH in the regimen significantly reduced 67 
the Cmax and the area under the serum concentration-time curve of RMP in the mice (4) 68 
leading to higher relapse rates. The antagonism between INH and RMP-PZA was due to a 69 
negative interaction between INH and PZA in the combination and the effect was INH dose 70 
dependent (5). It was not clear what interaction INH has with each of the components in the 71 
regimens. To provide greater clarity, it is important to identify and evaluate the level of 72 
persistent bacilli after chemotherapy. This information is of clinical importance since 73 
combination therapy involving RMP-INH-PZA is commonly employed. Using appropriate 74 
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drug-combinations has the potential to maximise therapeutic effects whilst minimising side 75 
effects of multiple drug therapy. Furthermore, evaluation of post-treatment persister levels 76 
may serve as a biomarker to predict relapse rate (6). In this study, we examined the 77 
therapeutic effects of each of the components singly, in two-drug and three-drug 78 
combinations using a modified Cornell mouse model. We evaluated persistent M. 79 
tuberculosis using culture filtrate which was shown by others (7) to contain resuscitation 80 
promoting factors (RPF) in mouse organs from a population of mice of which a sample had 81 
apparently culture negative organs after long-term chemotherapy.  82 
MATERIALS AND METHODS 83 
Bacterium and growth condition. M. tuberculosis strain H37Rv was mouse-passaged and 84 
grown in 7H9 medium supplemented with 10% albumin dextrose complex (ADC; Becton 85 
and Dickinson, UK) and containing 0.05% Tween 80 at 37°C without disturbance for 15 86 
days. The culture was subsequently frozen at -70°C for storage. To determine the viable 87 
counts prior to infection, colony forming unit (CFU) counting was performed prior to 88 
freezing and once again after thawing.  CFU counts were carried out by plating serial 10-fold 89 
dilutions of the cultures on 7H11 agar medium supplemented with oleic albumin dextrose 90 
complex (OADC, Becton and Dickinson, UK). Colonies were counted after incubation of 91 
the plates at 37°C for 3 to 4 weeks and viability was expressed as Log CFU/ml.  The cultures 92 
were subsequently diluted in phosphate-buffered saline (PBS) and used for inoculations in 93 
mice.   94 
Modified Cornell mouse model.  Rifampicin, isoniazid and pyrazinamide were tested singly 95 
or in double (RMP-INH, RMP-PZA and INH-PZA) or triple (RMP-INH-PZA) combinations 96 
using a modified Cornell mouse model which was based on the model previously established 97 
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in Cornell University (8, 9).   The model was conducted using the experimental design and 98 
procedure described below. 99 
  (i) Infection of mice.  Female BALB/c mice (6 to 8 weeks old) were obtained from Harlan 100 
UK Ltd. A total of 364 mice was infected intravenously via the tail vein with 1.2 × 105 CFU 101 
of mouse-passaged M. tuberculosis strain H37Rv per mouse as described previously (8, 10, 102 
11).   The animal husbandry guidelines and all animal experiments were performed according 103 
to the Animals Scientific Procedures Act, 1986 (an Act of the Parliament of the United 104 
Kingdom 1986 c. 14) (Home Office Project licence Number 70/7077) with approval from St 105 
George’s, University of London ethics committee.  106 
  (ii) Chemotherapy. As shown in Table 1, mice were randomly allocated into eight groups. 107 
Control group consisted of infected and untreated mice; 4 of these were sacrificed at 2 hours 108 
after infection (D0) and 4 were killed at the beginning of treatment, D14 and D21 days after 109 
infection. The treatment groups were as follows: single drug treatment group, each contained 110 
16 mice receiving RMP, INH or PZA, respectively, for 8 weeks. Combination groups, each 111 
contained 76 mice were administrated with RMP-INH, RMP-PZA, INH-PZA or RMP-INH-112 
PZA, respectively, for 14 weeks. Single drug therapy started 14 days after infection, when a 113 
large bacterial load in the organs (the mean CFU counts reached 107 per lung or spleen) had 114 
been achieved with visible symptoms of disease. Combination therapy started at 21 days after 115 
infection. All groups were treated by daily oral administration (0.2 ml) for 5 days per week at 116 
the dosages of RMP 10 mg/kg, INH 25 mg/kg or PZA 150 mg/kg. The drug suspensions 117 
were prepared freshly for the daily dosage. In the combination containing RMP, RMP was 118 
administered 1 hour before the other drugs to avoid drug to drug interactions (4). 119 
Immediately after termination of 14 weeks of chemotherapy, the remaining mice were 120 
administered 0.5 mg/mouse of hydrocortisone acetate by daily oral administration for 8 121 
6 
weeks to suppress host immune response.  CFU counts from lungs and spleens were 122 
performed to determine disease relapse.  123 
  (iii) Assessment of infection and treatment efficacy.  As seen in Table 1, to examine M. 124 
tuberculosis infection and baseline CFU counts before initiation of chemotherapy, 4 untreated 125 
control mice were sacrificed at 2 hours, day 14 and day 21 after infection, respectively. For 126 
assessment of treatment efficacy, 4 mice were sacrificed at the 2, 4, 6 and 8 weeks post 127 
treatment for single drug treatment to monitor CFU counts. For combination therapy, a 128 
sample of 8 mice was sacrificed at 2, 4, 6 and 8 weeks and 10 mice were used at 11 and 14 129 
weeks of treatment (Table 1). Lungs and spleens from mice were removed rapidly after 130 
sacrifice and a sterile autopsy was performed. The organs were transferred into 2 ml tubes 131 
each containing 1 ml sterile distilled water and 2 mm diameter glass beads. Lungs and 132 
spleens of mice were homogenised using a reciprocal shaker (Thermo Hybaid Ltd) for 40 133 
seconds at 6.5 speed. CFU counts from each lung and spleen were performed using serial 134 
dilutions of the homogenates. At 14th week treatment, the entire organ homogenates (the total 135 
volume of each organ homogenate was approximately 1.5 ml including the organ and 1 ml of 136 
water) from the 10 mice were aliquoted equally into three tubes which were used  1. CFU 137 
counting by addition of the homogenate to 2 ml of sterile distilled water following by plating 138 
out the entire organ homogenate suspension on 6 selective 7H11 agar plates,  2.  culturing in 139 
5 ml of selective Kirchner liquid medium by the addition of polymyxin B 200 U/ml, 140 
carbenicillin 100 mg/L, trimethoprim 20 mg/L and amphotericin B 10 mg/L  (Selectatab, 141 
Mast Diagnostica GmbH) for 4 weeks with subsequent sub-culturing of the entire culture 142 
onto Löwenstein-Jensen slopes for a further 4 weeks and 3. resuscitation of persistent bacteria. 143 
Culture negative organs were defined as no colonies grown on 7H11 agar plates and no 144 
growth in selective Kirchner liquid medium following inoculation on Löwenstein-Jensen 145 
slopes.   146 
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Selection of RMP- and INH-resistant mutants in mice. At 4th, 6th and 8th week post 147 
treatment, mouse lung and spleen homogenates were plated on 7H11 plates containing RMP 148 
or INH concentration at  two fold serial dilution from 1 to 64 mg/L. Colonies from the plates 149 
containing MIC value higher than 4 folds were picked and regrown in 7H9 medium. MIC 150 
was retested on RMP or INH containing 7H11 agar plates.  151 
Resuscitation of M. tuberculosis in mouse lungs and spleens. For resuscitation of M. 152 
tuberculosis grown in mouse organs, culture filtrates containing RPFs were used as described 153 
previously (6, 7).  M. tuberculosis H37Rv was grown in 7H9 medium for 15 to 20 days until 154 
an optical density of 1 to 1.5 was reached.  The cultures were harvested by centrifugation at 155 
3000 g for 15 minutes and sterilised by filtration with 0.2 µm filter (Sartorius) twice. The 156 
sterilised culture filtrates were made selective by addition of polymyxin B 200000 U/L, 157 
carbenicillin 100 mg/L, trimethoprim 20 mg/L and amphotericin B 10 mg/L (Selectatab, Mast 158 
Diagnostica GmbH) and immediately used for  broth counting of the most probable number 159 
(MPN) of the bacilli (7).  Broth counting of lungs and spleens after 14 weeks of combination 160 
therapy was performed as serial 10-fold dilutions in triplicate in which 0.5 ml of tissue 161 
homogenates were added to 4.5 ml of the culture filtrates. At 10-day intervals over a 2-month 162 
period of incubation at 37°C, the broth cultures were examined for visible turbidity changes. 163 
Growth of M. tuberculosis in turbid tubes was confirmed by colonial morphology on 7H11 164 
agar plates. The MPN of viable bacilli was then estimated from the patterns of positive and 165 
negative tubes (7). The absence of microorganisms other than mycobacteria from turbid tubes 166 
was confirmed by plating on blood agar medium (Oxoid) and Sabouraud dextrose agar 167 
(Oxoid).  In order to assess the sterility of culture filtrates free of M. tuberculosis, tubes 168 
containing culture filtrates were incubated at 37°C for 2 months to ensure  the absence of M. 169 
tuberculosis in the culture filtrates.  170 
8 
Statistical analysis. A simple model for monoexponential bacterial growth and elimination 171 
(12) (Fig 1) was fitted to the profiles of CFU vs. time obtained experimentally. As 172 
simultaneously occurring exponential replication and death rates cannot be differentiated with 173 
this type of data, a “knet” exponential rate constant was estimated separately before treatment 174 
began (“knet_no_drug” where it would take a net positive value) and during treatment 175 
(“knet_with_drug” where it would take negative value). During therapy, knet is a 1st order 176 
elimination rate constant which can be interpreted as the slope of the modelled line fit 177 
through the logarithmic-transform of the data (with units in these data of wk-1).  Parameter 178 
estimation was carried out with nonlinear regression using the nonlinear least squares 179 
optimisation function “lsqnonlin” as part of the “pracma” package in the R statistical 180 
software language, with an objective function weighted by 1/(predicted value)^2. Standard 181 
errors of parameter estimates were calculated using the method outlined by Landaw et al. (13) 182 
with the Jacobian of model parameter sensitivities estimated using a numerical central 183 
difference method. The datasets comprised from multiple individual subject animals were 184 
treated as a naïve pool for data analysis purposes (14) rather than using the average of the 185 
data at each time-point. The significance of differences between model parameter estimates 186 
under different therapies was examined with pairwise Z-tests incorporating a Bonferroni 187 
correction of 21, where P values <0.002 would be considered significant. The significance of 188 
differences between the relapse rates was determined with pairwise Fisher’s exact tests with a 189 
Bonferroni correction of 6, with P values <0.008 considered significant. 190 
RESULTS 191 
Survival of mice.  During treatment, 4 mice died in the group of RMP-INH (1 at 9 weeks, 1 192 
at 10 weeks and 2 at 12 weeks, 2 mice died in RMP-PZA (1 at 10 weeks and 1 at 12 weeks) 193 
and 3 mice died in the group of INH-PZA (1 at 9 weeks, 1 at 10 weeks and 1 at 13 weeks). 194 
The reason for the death was unknown but was most likely due to natural causes such as 195 
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tumour development or neurological disorders and was unrelated to tuberculosis or treatment. 196 
As the time of death was uncertain and also not at the sampling time point, organ bacterial 197 
counts were not determined from these animals. No mortality was observed during the course 198 
of single drug and RMP-INH-PZA treatments.  199 
Treatment with RMP, INH and PZA singly and in two drug or three drug combination 200 
in a modified Cornell mouse model. We investigated the effect of RMP, INH and PZA 201 
singly and in double and triple combinations on the rate of bacterial eradication and relapse in 202 
a modified Cornell mouse model.  The single dose of the drugs was tested in the animals for 203 
8 weeks and terminated before resistant strain emergence (15). As shown in Table 2, Table 3 204 
and Fig 2, RMP at 10 mg/kg, INH at 25 mg/kg or PZA at 150 mg/kg exhibited modest rates 205 
of bacterial eradication in both lungs and spleens showing 99% kill (2-log reduction)  at 206 
around 8 weeks. The exponential rate constants (logarithmic base 10) for net bacterial 207 
elimination during treatment (knet_with_drug) for RMP, INH and PZA were -0.21, -0.27 and -208 
0.26 for lungs and -0.31, -0.29 and -0.26 for spleens (Table 4), respectively.  Notably, the 209 
drop in CFU counts in both lungs and spleens during the first 2 weeks of treatment with the 210 
singly dosed drugs was minimal, though over the complete time course of therapy a clear 211 
monoexponential decline in CFU counts was observed. No RMP or INH resistant strains 212 
were isolated from 4 to 8 weeks of treatment.  In addition, there was no significant difference 213 
in activities amongst each of the single drug treatments (Table S1 and S2 in the supplemental 214 
material). Interestingly, treatment with RMP combined with INH (Fig. 2A and 2E) or PZA 215 
(Fig. 2B and 2F) accelerated the rate of bacterial eradication showing 99% kill (Table 2 and 216 
Table 3) at 4 weeks of treatment for RMP-INH and at about 3 weeks for RMP-PZA with the 217 
estimation of knet_with_drug at -0.53 and -0.51 for lungs and -5.2 and -0.43 for spleens (Table 4), 218 
respectively. All the combined therapies were significantly more effective than the single 219 
therapy (Table S1 and S2 in the supplemental material). As seen in Table 2, Table 3,  Fig. 2C 220 
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and Fig. 2G, 99% kill with the RMP-INH-PZA combination was achieved at  about 3 weeks 221 
for both lungs and spleens showing a similar elimination rate constant  (-0.51 for lung and -222 
0.48 for spleen) to RMP-INH or RMP-PZA (Table 4 ).  There was no significant difference in 223 
efficacies amongst these RMP containing regimens against M. tuberculosis in this mouse 224 
model (Table S1 and S2 in the supplemental material). All the RMP containing combinations 225 
achieved undetectable M. tuberculosis CFU counts (Table 2 and Table 3) and negative broth 226 
growth in selective Kirchner liquid medium in murine lungs and spleens at 14 weeks of 227 
treatment. However, when INH was combined with PZA (Fig. 2D and 2H), there was no 228 
noticeably increased initial kill compared to each of the single drugs until 4 weeks of 229 
treatment followed by a reduction of CFU count showing a 99% kill at 5.6  weeks post 230 
treatment (Table 2) for lungs and 4 weeks for spleens (Table 3). This was reflected in the 231 
estimates for knet_with_drug for the INH and PZA combination, which was -0.42 and -0.44 for 232 
lungs and spleens, respectively (Table 4). Although the INH and PZA combinations failed to 233 
achieve undetectable M. tuberculosis CFU counts in murine lungs after 14 weeks of treatment 234 
(Fig. 2D and 2H), the difference in efficacies between the single drug treatment and the 235 
combination was significant (Table S1 and S2 in the supplemental material).  236 
Relapse rate of treatment with RMP-INH, RMP-PZA and RMP-INH-PZA in the 237 
modified Cornell mouse model. After 8 weeks of immunosuppression with high dosage 238 
steroid, disease relapse rates for the treatments with double and triple regimens were 239 
determined by the percentage of mice that developed positive M. tuberculosis CFU counts in 240 
lungs, spleens or both. The organ relapse proportions for the four regimens are shown in 241 
Table 5. The treatment with the regimens of RMP-INH, RMP-PZA and RMP-INH-PZA 242 
yielded similar relapse rates at 85, 77.3 and 87.5%, respectively.  These relapse rates were not 243 
significantly different amongst the three drug regimens or to a 100% relapse rate (P>0.002 244 
for Fishers exact test including Bonferroni correction for multiple pairwise tests). The INH 245 
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and PZA combination was not able to produce negative organ CFU count at the termination 246 
of the 14 week treatment (Table 2 and Table 3).  247 
Determination of persisters after treatment with four drug regimens. In order to 248 
determine the effect of the four combination regimens on the post-treatment level of 249 
persisters, we analysed lung and spleen homogenates at 14 weeks post-treatment using M. 250 
tuberculosis culture filtrate resuscitation (6). As shown in Table 6, at 14 weeks post-treatment, 251 
although CFU counts and growth in Kirchner liquid medium were negative for the drug 252 
regimens INH-RMP, RMP-PZA and INH-RMP-PZA, there were significant amounts of 253 
culture filtrate-dependent persisters present  in lungs and spleens (1.89 log cells/lung and 2.09 254 
log cells/spleen for RMP-PZA,  2 log cells/lung and 2.18 log cells/spleen for INH-RMP and 255 
1.94 log cells/lung and 2.12  log cells/spleen for INH-RMP-PZA). After INH-PZA treatment, 256 
there were 4 log culture filtrate-resuscitated bacilli in both lungs and spleens. If we exclude 257 
CFU count positive bacilli, there were still 4-log culture filtrate-dependent persisters in the 258 
organs of INH-PZA treated mice.  259 
DISCUSSION 260 
In this study, we re-evaluated the current TB treatment regimen and studied the drug 261 
interactions by comparing the bacterial elimination rates, the number of culture filtrate-262 
dependent bacteria present at treatment completion  and relapse rates with different therapies 263 
in a mouse tuberculosis treatment model based on the model established at Cornell University  264 
over a half century ago (8, 9). This model enables us to determine anti-TB activities of 265 
combination regimens and, importantly, to measure relapse rates. It is characterized by the 266 
inoculation of a large number of bacteria intravenously to initiate an infection and the 267 
treatment of the disease once the infection has been established (2 to 3 weeks post infection).  268 
In this model, an intensive treatment is able to render mouse organs culture-negative on agar 269 
plates and in broth culture lacking culture filtrate, but fails to prevent relapse (10, 11).  270 
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However, these apparently culture-negative organs contained viable bacteria that could be 271 
cultivated by supplementing broth media with culture filtrate (6) containing RPFs (7). 272 
Significantly, we found that when RMP was combined with INH, PZA or INH-PZA, 273 
significant additive activities were observed compared to each of the single drug treatments. 274 
However, the combination of INH and PZA showed a less significant additive effect to either 275 
of the single drug treatments. The combination regimens of RMP-INH, RMP-PZA and RMP-276 
INH-PZA exhibited equivalent treatment efficacies with very similar relapse rates which 277 
could not actually be differentiated from a 100% relapse rate, while INH-PZA failed to 278 
render organ culture negative after 14 weeks of treatment.  Rifampicin-containing regimens 279 
reduced the number of culture filtrate-dependent persisters to a greater extent than INH-PZA, 280 
but did not eliminate them from mouse organs by the end of 14 weeks of treatment.   281 
In humans, the key for treatment success depends on the bactericidal drugs INH and RMP 282 
which rapidly kill actively replicating bacilli in cavities and control disease progression (16) 283 
within the first two months of chemotherapy. This is defined by negative acid fast staining in 284 
sputum. In fact, bactericidal drugs such as INH exhibit bactericidal activity during the first 2 285 
days of monochemotherapy (17). The need for prolonged treatment is due to the emergence 286 
of persistent bacilli which may arise in the heterogeneity of host environments (18). These 287 
persistent tubercle bacilli are undetectable by the traditional microbiological methods and 288 
become profoundly tolerant to bactericidal drugs (10).  Sterilizing drugs such as PZA and 289 
RMP contribute to shortening of the treatment duration (18). However, in our study, 290 
comparing elimination rate constants for monotherapies in mice, there was no significant 291 
difference between RMP, INH or PZA. There was no superior bactericidal activity of INH, 292 
which contrasts with the effect of INH in humans. This indicates that treatment profiles are 293 
different between mice and humans.  294 
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Synergistic drug interactions have not been demonstrated in the treatment of TB in mice. It is 295 
generally accepted that more than a 2 log kill compared to the single drug defines a 296 
synergistic combination (19). Here we showed that enhanced bactericidal activities were 297 
achieved when RMP was combined with INH or PZA.  Estimates of the elimination rate 298 
constant for all the combinations were significantly faster (P < 0.0001) than all single drugs 299 
(Table S1 and S2 in the supplemental material) showing 99% kill of the bacilli (a 2 log kill) 300 
achieved 4 to 5 weeks earlier than monotherapies. The activities of the combinations namely 301 
RMP-INH, RMP-PZA and RMP-INH-PZA shown by the value of the exponential 302 
elimination rate constant (Table 4) demonstrated significant additive interactions on the 303 
original scale. It is interesting therefore that the INH-PZA combination showed less enhanced 304 
effect than the singly dosed drugs at the earlier stage of treatment when there was a large 305 
number of actively growing organisms (10) and its increased efficacy compared to the 306 
monotherapies was more apparent after 6 weeks of treatment. This was in agreement with the 307 
previous findings that INH and PZA combination was more efficacious than the single drug 308 
in the reduction of organ bacterial counts and prevention of relapse rates in mice (8, 20) and 309 
in humans (21-23). Efficacy of all RMP containing regimens (INH-RMP, RMP-PZA and 310 
INH-RMP-PZA) in mouse tuberculosis treatment was very similar (P>0.05) as shown by the 311 
similarity of the elimination rate constants, which confirmed previous findings (3, 4) while 312 
INH-PZA therapy was less effective than other combination therapies (P < 0.001) (5).  At the 313 
end of 14 weeks of treatment, lungs and spleens of mice treated with RMP/INH, RMP/PZA 314 
or RMP/INH/PZA became CFU count and broth count negative, conversely, the INH and 315 
PZA combination failed to achieve culture negativity in the mouse organs. After 8-weeks of 316 
steroid treatment, tubercle bacilli were found in the organs of mice treated with RMP/INH, 317 
RMP/PZA or RMP/INH/PZA. Although the elimination rates of the rifampicin containing 318 
regimens (RMP-INH, RMP-PZA and RMP-INH-PZA) displayed significant differences to 319 
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INH/PZA (the latter regimen having failed to achieve culture negativity), their relapse rates 320 
could not be differentiated from a 100% relapse rate at the numbers of mice examined in this 321 
study. This is attributable to the presence of persistent bacteria in the RMP-containing 322 
regiments which could only be resuscitated by culture filtrate (Table 6). This observation 323 
coincided with the previous finding that early bactericidal activities of certain novel drug 324 
regimens were not necessarily predictive of a sterilizing effect (24) which may be attributed 325 
to the inability of the drug regimens to eliminate the persistent bacilli which were 326 
undetectable using our traditional microbiological methods. Recently, we showed that faster 327 
elimination rates derived from high dose RMP treatment led to elimination of persistent 328 
bacteria and this contributed to a shortened chemotherapy and a reduced relapse rate (6).  It is 329 
not known if the elimination rate of culture filtrate-dependent bacteria is likely a surrogate 330 
measure of the sterilizing activity of the regimens as this has not been determined.  RMP-331 
containing regimens resulted in faster elimination rates than INH-PZA against plate-332 
cultivable and reduced culture filtrate-dependent sub-populations at 14 weeks of treatment. 333 
Clearly further study is required to demonstrate if elimination rate of culture filtrate-334 
dependent bacteria is a better surrogate for sterilizing effect.  335 
The major caveat of this study was the relatively short period of chemotherapy in which INH-336 
PZA failed to achieve CFU count negative mouse organs, this made it difficult to compare 337 
relapse of all the treatment regimens. It is likely that a difference in the sterilizing activity of 338 
these regimens would emerge with longer durations of treatment.  Future work aiming to use 339 
a larger number of mice and longer treatment duration would illustrate more clearly the 340 
relationship between elimination rate and relapse amongst different drug regimens.  341 
Bacterial population dynamics in infected animals is expected to be complex and related to 342 
the density and composition of the infecting population. In this study, the route of infection 343 
was systemic which was performed according to the previously established method (8, 9). 344 
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Previous studies showed that intravenous infection of M. tuberculosis in mice led to slower 345 
disease progression in lungs (25) in spite of a high level of systemic immunity. However, 346 
low-dose aerosol infection resulted in substantially more virulent of M. tuberculosis in mouse 347 
lungs (25). In aerosol infected mice, a low number of bacilli was seeded in the lung and these 348 
then multiply into larger populations (25) presumably with smaller sub-populations of 349 
persistent organisms. It has been shown that slower bactericidal rates of combination 350 
regimens were found in intravenously infected mice with a higher relapse rate than aerosol 351 
infected animals (26). The difference might be due to different immune responses produced 352 
between intravenous and aerosol infected animals. It is not known if different routes of 353 
infection affect the level of culture filtrate-dependent persisters. Future work will be 354 
conducted to compare persistent M. tuberculosis levels in mice using respiratory and 355 
systemic infections.  356 
It has been shown that antagonism occurred between INH and the combination RMP-PZA in 357 
the treatment of tuberculosis in mice (4). The authors suggested that the antagonistic effect 358 
was partially derived from the interaction of INH with RMP as addition of INH significantly 359 
reduced the Cmax and AUC of RMP (4).  There was also a negative interaction between INH 360 
and PZA against M. tuberculosis (5) in mice when higher dose of INH was used.  In contrast, 361 
a separate study showed that the RMP-PZA was less effective than RMP-INH-PZA 362 
combination in mouse models with both aerosol and intravenous infections indicating that 363 
inclusion of INH in the regimen showed no negative interaction to RMP-PZA (26). 364 
Observation of CFU counts over time with RMP-INH, RMP-PZA and RMP-INH-PZA, 365 
RMP-PZA treatment showed increased reduction in CFU counts compared to RMP-INH and 366 
RMP-INH-PZA especially in week 2, 4 and 6 of treatment (Fig. 2), indicating that INH was 367 
slightly antagonistic.  However, our data demonstrated that  this antagonistic effect when 368 
INH is added to the RMP-PZA regimen was not significant based on comparison of the 369 
16 
elimination rate constants estimated from the profiles of bacterial elimination over time; the 370 
knet_with_drug was -0.51  for RMP-PZA and -0.51 for RMP-INH-PZA (significance of 371 
difference p>0.002). We also observed that the INH-PZA combination was not antagonistic 372 
against M. tuberculosis compared to the activities of each single drug. The differences in drug 373 
interaction of the current regimens seen from different studies may be attributable to different 374 
experimental conditions such as M. tuberculosis strains, mouse species, routes of infection 375 
and length of treatment used by different research groups (26).  Importantly, our 376 
demonstration of RMP containing regimens being superior to a RMP-free regimen against M. 377 
tuberculosis in the modified Cornell mouse model indicated the essential role RMP plays in 378 
the current regimen to treat tuberculosis disease.  However, the relationship between 379 
elimination rate, MPN counts and relapse rates requires further evaluation across a broader 380 
range of (possibly non-RMP containing) regimens. 381 
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Figure legend 471 
Figure 1. A simple mathematical model for exponential growth and decline of bacteria 472 
Figure 2. Treatment profiles of M. tuberculosis H37Rv with RMP, INH and PZA singly or in 473 
combination in the modified Cornell mouse model. The results of a single experiment are 474 
shown with viability expressed as log CFU counts per lung or per spleen.  Mice were infected 475 
intravenously at week -2 or -3 and the infection was allowed to progress for 2 or 3 weeks 476 
prior to treatment with RMP, INH and PZA singly or in combination indicated as a solid 477 
arrow for 14 weeks (time weeks 0 – 14).  At week 2, 4, 6, 8, 11 and 14 of post treatment, 478 
CFU counts in the organs from each treatment group were estimated. Steroid treatment was 479 
started immediately after the termination of 14 weeks of antibiotic treatment as indicated with 480 
an empty arrow.  A. treatment with RMP, INH and RMP-INH in lungs. B, treatment with 481 
RMP, PZA and RMP-PZA in lungs. C. treatment with RMP, INH, PZA and RMP-INH-PZA 482 
in lungs. D. treatment with INH, PZA and INH-PZA in lungs. E. treatment with RMP, INH 483 
and RMP-INH in spleens. F, treatment with RMP, PZA and RMP-PZA in spleens. G. 484 
treatment with RMP, INH, PZA and RMP-INH-PZA in spleens. H. treatment with INH, PZA 485 
and INH-PZA in spleens.  486 
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TABLE 1. Mouse tuberculosis experimental design 
Treatment groupsa Total No. of miceb D0 D14 D21 2W 4W 6W 8W 11W 14W 22Wc
Control 12 4 4 4 
RMP 16 4 4 4 4 
INH 16 4 4 4 4 
PZA 16 4 4 4 4 
RMP-INH 76 8 8 8 8 10 10 24 
RMP-PZA 76 8 8 8 8 10 10 24 
INH-PZA 76 8 8 8 8 10 10 24 
RMP-INH-PZA 76 8 8 8 8 10 10 24 
 
a Mice were intravenously infected at day 0. Treatment commenced at 14 days after infection for single 
drug therapy and 21 days for combination therapy. Dosages for each drug were as follows: RMP 10 
mg/kg, INH 25 mg/kg and PZA 150 mg/kg. 
b  Total mice were infected and treated excluding natural death of the mice during the course of 
treatment  
c  8 weeks of hydrocortisone treatment post 14 weeks of treatment 
 
TABLE 2. Bactericidal and sterilising activities of experimental regimens against M. tuberculosis in mouse lungs 
Time of infection 
and treatment 
Mean Log CFU per lung ± SD 
Control RMP INH PZA RMP-INH RMP-PZA INH-PZA RMP-INH-PZA 
D0a 4.38 ± 0.04 
D14b 6.86 ± 0.13 
D21c 7.04 ± 0.01 
W2d 6.48 ± 0.14 6.83 ± 0.25 6.87 ± 0.13 6.05 ± 0.07 5.66 ± 0.13 6.84 ± 0.04 6.10 ± 0.16 
W4 5.40 ± 0.15 5.57 ± 0.37 5.32 ± 0.15 5.05 ± 0.07 4.26 ± 0.08 5.46 ± 0.24 4.63 ± 0.17 
W6 5.37 ± 0.29 5.27 ± 0.70 5.19 ± 0.35 3.64 ± 0.12 3.46 ± 0.18 5.16 ± 0.04 3.81 ± 0.14 
W8 5.18 ± 0.13 4.89 ± 0.40 5.05 ± 0.15 3.12 ± 0.21 2.73 ± 0.22 3.83 ± 0.07 2.32 ± 0.24 
W11 1.20 ± 0.27 0.77 ± 0.48 2.54 ± 0.12 0.63 ± 0.70 
W14e 0 0 1.82 ± 0.42 0 
 
 a. 2 hours post-infection. b. 14 days  post-infection. e. 21 days post-infection. d. week 2 post-treatment. e. CFU counts were derived from one 
third of tissue homogenate and limit detection was 3 CFU/lung. 
 
 
TABLE 3. Bactericidal and sterilising activities of experimental regimens against M. tuberculosis in mouse spleens 
Time of infection 
and treatment 
Mean Log CFU per spleen ± SD 
Control RMP INH PZA RMP-INH RMP-PZA INH-PZA RMP-INH-PZA 
D0a 5.32 ± 0.04 
D14b 7.06 ± 0.01  
D21c 7.22 ± 0.21 
W2d 6.66 ± 0.06 6.85 ± 0.15 6.45 ± 0.51 5.59 ± 0.14 5.07 ± 0.12 6.14 ± 0.17 5.57 ± 0.15 
W4 5.49 ± 0.10 5.58 ± 0.30 5.89 ± 0.10 4.52 ± 0.14 3.99 ± 0.22 5.29 ± 0.25 4.15 ± 0.10 
W6 4.90 ± 0.24 5.19 ± 0.19 5.46 ± 0.24 3.52 ± 0.20 2.71 ± 0.45 5.01 ± 0.08 3.15 ± 0.29 
W8 4.80 ± 0.24 4.99 ± 0.16 5.06 ± 0.08 3.01 ± 0.11 1.95 ± 0.19 4.57 ± 0.06 1.99 ± 0.07 
W11 0.78 ± 0.50 0.64 ± 0.69 2.53 ± 0.43 0.73 ± 0.49 
W14e 0 0 1.52 ± 0.50 0 
a. 2 hours post-infection. b. 14 days  post-infection. c. 21 days post-infection. d. week 2 post-treatment. e. CFU counts were derived from one 
third of tissue homogenate and limit detection was 3 CFU/spleen. 
 
TABLE 4. Estimates of exponential rate constants during pre-treatment (knet_no_drug) and treatment (knet_with_drug) in mouse lungs and 
spleens 
Treatmenta 
knet_no_drug in Lungs 
(week-1) 
knet_with_drug in lungs 
(week-1) 
knet_no_drug in spleens 
(week-1) 
knet_with_drug in spleens 
(week-1) 
est.b %RSEc est.b %RSEc est.b %RSEc est.b %RSEc 
RMP 1.03 1.99 -0.21 8.22 1.08 3.15 -0.31 6.09 
INH 1.03 1.99 -0.27 10.37 1.08 3.15 -0.29 6.35 
PZA 1.03 1.99 -0.26 9.05 1.08 3.15 -0.26 5.92 
RMP-INH 0.85 5.05 -0.53 2.61 0.58 0.91 -0.52 2.15 
RMP-PZA 0.85 5.05 -0.51 1.65 0.58 0.91 -0.43 4.95 
INH-PZA 0.85 5.05 -0.42 3.00 0.58 0.91 -0.44 4.38 
RMP-INH-PZA 0.85 5.05 -0.51 2.91 0.58 0.91 -0.48 3.23 
 
a single drug treatments for 8 weeks. Double and triple drug treatments for 14 weeks. b estimate. c percentage relative standard error. 
TABLE 5. Relapse of mice after double or triple drug treatment 
Positive culture from RMP-INH RMP-PZA RMP-INH-PZA 
Spleen only 8 6 15 
Lung only 5 4 1 
Both organs 4 7 5 
Neither organs 3 5 3 
Total No. of mice with positive cultures 17 17 21 
Total No. of mice 20 22 24 
Relapse (%) 85 77.3 87.5 
 
P values of relative relapse rates determined by Fisher’s exact test: RMP-INH/RMP-PZA 0.7, 
RMP-INH/RMP-INH-PZA 1.0 and RMP-PZA/RMP-INH-PZA 0.45. With Bonferroni 
correction P <0.008 would considered significant.  
TABLE 6. Resuscitation of M. tuberculosis H37Rv in mouse lungs and spleens of a modified 
Cornell mouse model after treatment with different drug regimens 
Lung Spleen 
Drug regimensa Plate countsb Broth counts RPFc Plate countsb Broth counts RPFc 
RMP-PZA 0 1.89±0.12 0 2.09±0.29 
INH-RMP 0 2.00±0.14 0 2.18±0.32 
INH-RMP-PZA 0 1.94±0.14 0 2.12±0.26 
INH-PZA 1.82±0.42 4.10 ±0.09 1.52±0.5 4.07±0.15 
 
a 14 week treatment 
b determined by CFU counts of the organ homogenies (n=10) on 7H11 agar plates, Mean Log 
CFU/organ ± standard deviations. CFU counts were derived from one third of tissue 
homogenate and calculated to represent the counts of entire organ. The limit of detection was 
3 CFU/organs.  
c determined by MPN of the diluted organ homogenies (n=10)  with the culture filtrates, 
Mean of Log MPN/organ ± standard deviations. Broth counts were derived from one third of 
tissue homogenate and calculated to represent the MPN of entire organ. The limit of detection 
was 10 MPN/organ.  
 
